JaLCDOI 10.18926/AMO/32429
FullText URL fulltext.pdf
Author Takahashi, Isao| Kohi, Fumikazu| Inagaki, Noritoshi| Ohmoto, Eijiro| Fukumoto, Mitsuhiro| Watanabe, Seiichiro| Takaoka, Kazuko| Kitajima, Koichi| Kimura, Ikuro| Sanada, Hiroshi|
Abstract <p>The O2- production by neutrophils was examined in 4 cases of refractory anemia with excess of blasts (RAEB) in order to evaluate the possible causes of enhanced susceptibility to infection and to gain some informations on the differentiation of neutrophils in this hematological disorder. In three of the four RAEB cases there was little O2- production by neutrophils, in addition to there being morphological anomalies of the neutrophils such as a Pelger-Huet-like anomaly, granular deficiency and binucleated cells. These results suggest that the impairment of O2- production by neutrophils in RAEB is one of the possible causes of susceptibility to infection and also suggest that the differentiation of neutrophils in this hematological disorder is faulty. The estimation of O2- production by neutrophils may be a useful diagnostic method for preleukemia.</p>
Keywords superoxide anion refractory anemia with excess of blasts (RAEB) preleukemia
Amo Type Article
Published Date 1983-10
Publication Title Acta Medica Okayama
Volume volume37
Issue issue5
Publisher Okayama University Medical School
Start Page 417
End Page 421
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 6316758
Web of Sience KeyUT A1983RN98400005
JaLCDOI 10.18926/AMO/30705
FullText URL fulltext.pdf
Author Takahashi, Isao| Hara, Masamichi| Uchida, Kozaburo| Takaoka, Kazuko| Watanabe, Seiichiro| Lai, Minyu| Hamasaki, Kazuhide| Kohi, Fumikazu| Kitajima, Koichi| Kimura, Ikuro| Adachi, Tomiro| Yorimitsu, Seiichi| Tokioka, Masaaki| Sanada, Hiroshi|
Abstract <p>Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%). The time required for achieving the complete remission varied from 20 to 55 days with a median of 39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks. Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients, although they were managed by symptomatic treatment. The results indicate the effectiveness of this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.</p>
Keywords aclarubicin cytosine arabinoside chemotherapy acute myelocytic leukemia
Amo Type Brief Note
Published Date 1982-02
Publication Title Acta Medica Okayama
Volume volume36
Issue issue1
Publisher Okayama University Medical School
Start Page 77
End Page 80
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 6950658
Web of Sience KeyUT A1982NE20000009
JaLCDOI 10.18926/AMO/30544
FullText URL fulltext.pdf
Author Takahashi, Isao| Hara, Masamichi| Adachi, Tomiro| Takaoka, Kazuko| Sakano, Makoto| Lai, Miinyuh| Kohi, Fumikazu| Yorimitsu, Seiichi| Tokioka, Masaaki| Kitajima, Koichi| Kimura, Ikuro| Sanada, Hiroshi|
Abstract <p>Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia and 5 patients with acute lymphocytic leukemia) were treated with a new anthracycline antibiotic, aclacinomycin-A (ACM). ACM was administrated by intravenous drip infusion at a dose of 20 mg/day for 7 or 14 days and this was repeated after at least 7 days. Four of 12 patients (33.3%) achieved a complete remission; 3 of 7 acute myelocytic leukemia (42.8%) and 1 of 5 acute lymphocytic leukemia (20.0%). The days required for achieving the complete remission ranged from 23 to 78 days (median: 61) and the total doses of ACM used from 180 to 500 mg (median: 310), and the durations of complete remission from 11 to 28+ weeks (median: 21+). The untoward effects on digestive organs, such as nausea, vomiting and anorexia, and hematological toxicities were frequently seen; however, they were controlled by supportive treatment. Alopecia was not observed. Arrythmia was recognized in one patient at the initiation of ACM infusion with complete remission without withdrawal of ACM. These results suggest that ACM is a potentially effective anthracycline antibiotic in the clinical management of acute leukemia.</p>
Keywords aclacinomycin-A leukemia chemotherapy
Amo Type Brief Note
Published Date 1980-11
Publication Title Acta Medica Okayama
Volume volume34
Issue issue5
Publisher Okayama University Medical School
Start Page 349
End Page 354
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 6449134
Web of Sience KeyUT A1980KT96800007